Innovation Is Easy, Governance Is Hard: AI’s Next Challenge in Healthcare (Part II)
Sorry, something went wrong with the purchase process. Please refresh the page and try again.
Please try again in a few minutes. Alternatively, you can contact our customer service.
-
Narrated by:
-
By:
Summary
- National strategy: China has elevated AI healthcare into a broader national agenda, linking it to economic modernization, tech leadership, and solving structural pressures like an aging population and uneven medical access.
- Multi-agency governance: Regulation involves the National Health Commission (clinical integration), NMPA (device approvals), and Cyberspace Administration (data and algorithms), with strong top-down coordination.
- Policy framework: A layered regulatory ecosystem—national strategies, healthcare rules, cybersecurity, and AI-specific policies—has replaced early innovation-focused guidelines, designed to evolve alongside the technology.
- Governance model vs. the West: China uses a centralized, speed-focused model, contrasting with the US market-driven approach and Europe's rights-focused framework.
- Advances: Rapid real-world scaling (imaging, drug discovery, hospital workflows) and structured approval pathways, supported by tight industry-regulator collaboration.
- Key challenges: Regulatory lag behind fast-moving generative AI, cross-agency alignment difficulties, unclear accountability, and the need to build long-term clinical trust.
- Comparative outlook: The global race is shifting from pure technology to a competition between governance models, where transparency and interoperability remain Western strengths.
- Next phase: Success will hinge on trust, responsible scaling, and multi-stakeholder collaboration, moving the conversation from “Can AI do this?” to “How do we use it responsibly?”
adbl_web_anon_alc_button_suppression_t1
No reviews yet